药物研发市场：按药物类型、技术和治疗领域分類的全球市场预测，2026-2032年

预计到 2025 年，药物研发市场价值将达到 811.1 亿美元，到 2026 年将成长至 925.3 亿美元，到 2032 年将达到 2098.7 亿美元，复合年增长率为 14.54%。

主要市场统计数据
基准年 2025	811.1亿美元
预计年份：2026年	925.3亿美元
预测年份 2032	2098.7亿美元
复合年增长率 (%)	14.54%

我们将总结推动创新发展的技术驱动因素、监管压力和策略重点，为下一代治疗和药物发现平台奠定基础。

随着生物学、工程学和资料科学的融合，从假设到先导化合物的发现途径不断拓展，药物研发格局正以前所未有的速度演变。检测自动化、计算化学和多组体学分析技术的进步正在缩短药物研发週期，而监管环境和支付方的期望则要求儘早展现转换价值。在此背景下，各机构必须应对从试剂采购到后期转化检验等各环节中错综复杂的科学机会与营运摩擦。

找出能够重塑药物发现工作流程并加速转化研究成果的变革性科学、技术和经营模式转变。

多项变革正在重塑药物研发的营运和策略格局。首先，高内涵资料流与机器学习的整合，使得假设生成和候选化合物筛选能够以前所未有的规模进行，从而将研究重点从偶然发现转向资料驱动的先导化合物筛选。其次，实验流程的模组化，结合自动化和标准化试剂，降低了实验的变异性，实现了跨地域实验的可重复性，进而促进了全球合作和快速迭代。

分析美国 2025 年的累积政策和关税变化及其对供应链、采购和製造策略的连锁反应。

2025年美国实施的政策变化和关税调整，为药物研发实验室广泛使用的试剂、设备和关键组件的采购带来了新的复杂性。关税调整影响了进口实验室设备和某些生化试剂，迫使采购团队重新评估供应商关係、前置作业时间和总到岸成本。为此，许多机构调整了筹资策略，强调双重采购、延长合约期限以及与供应商更紧密的合作，以确保获得优惠配额并减少供应中断。

识别药物类型、底层技术和治疗领域中以细分市场主导的机会领域，以帮助确定优先顺序和投资决策。

从细分市场的观点来看，不同细分市场在策略、能力投资和伙伴关係设计方面都面临着不同的挑战。就药物类型而言，生物製药和小分子药物的研发路径各不相同，这会影响上游药物发现的重点和下游的生产决策。生物製药通常需要对錶达系统和分析表征进行更深入的投入，而小分子药物则往往专注于药物化学、ADMET分析和可扩展的合成途径。从基础技术的角度来看，推动生物分析仪器、生物晶片和生物资讯学的平台整合，可以透过实现高解析度资料收集和自动化决策来创造价值。同时，组合化学和高通量筛检加速了化学多样性的探索和候选化合物的鑑定。奈米技术和药物基因体学进一步扩展了标靶递送和患者分层的工具箱，从而实现更精准的转化策略。

本研究检验了影响全球资源分配、临床试验施行地点和製造地。

区域趋势对组织机构的职能设定、试验进行地点和组件采购方式有显着影响。美洲地区创业投资、专业服务供应商和转化医学基础设施高度集中，能够支持从先导化合物发现到临床试验的快速转化，促进研发团队与临床合作伙伴之间的紧密协作。欧洲、中东和非洲（EMEA）地区拥有深厚的科学专长、多元化的法规环境以及对合作研究网络的重视，是开展联盟计画和适应性试验设计的理想区域。亚太地区拥有大规模的生产能力、快速发展的生物技术生态系统以及丰富的临床研究患者群体，是扩大生产规模和加速患者招募的策略性选择。

透过对主要企业参与者和创新合作伙伴进行分析，我们将揭示他们在药物发现生态系统中的竞争地位、伙伴关係趋势和能力差距。

针对企业和联盟的分析突显了能力集中的领域和仍然存在的差距。一些机构透过结合硬体、化学和数据分析的专有平台实现差异化，加速迭代式药物研发週期并提供独特的服务模式。另一些机构则透过策略合作拓展业务范围，建构包含外包研究服务提供者、学术合作伙伴和合约开发组织 (CDO) 的能力组合，从而在不承担全部固定成本的情况下利用专家知识。此外，一系列技术创新者正在推动检测灵敏度、小型化和通量的突破，迫使老牌公司重新评估其商业模式和投资重点。

我们提供切实可行的建议，帮助产业领导者调整开发平臺，降低供应链风险，并最大限度地发挥新兴平台技术的潜力。

产业领导者应谨慎采取措施，使科学研究目标与营运能力相符，同时确保在不确定的环境中拥有多种选择。首先，透过投资数据标准、模组化自动化和检验的分析方法，增强跨平台互通性，确保不同实验室和使用不同仪器产生的结果具有可比较性和可操作性。其次，减少对单一来源的依赖，并制定包含紧急时应对计画的采购和供应商发展策略，以因应跨国中断。第三，透过将临床导向的检测、患者来源模型和生物标记开发整合到药物研发流程中，并优先考虑早期转化检验，降低下游研究的失败率。

本文檔描述了为整合一手资料和二手资料而采用的严谨的混合方法研究途径，以确保研究结果的可重复性和策略有效性。

这些研究结果所依据的研究采用了混合方法，结合了访谈、技术文献整合和系统性的能力映射。访谈包括与药物研发人员、采购经理和监管专家进行结构化对话，以了解营运挑战和策略重点。二级资讯来源包括同行评审文章、监管指导文件和技术检验报告，用于检验技术声明并阐明创新路径。在资料整合过程中，优先考虑可重复性和可追溯性，将具体观察结果与资讯来源关联起来。

我们提供了一个综合考虑技术、监管和商业性因素的权威视角，为经营团队决策和策略蓝图。

总之，在当今药物研发时代，各机构必须兼具科学野心和运作严谨性。测量仪器、计算建模和转化生物学的突破性进展创造了前所未有的机会，但这些机会也受到价值链脆弱性、政策环境不断变化以及人们对早期临床意义日益增长的期望等现实因素的影响。那些能够整合互通平台、制定切实可行的伙伴关係策略并建立健全供应商管理体系的机构，将更有能力将药物研发成果转化为临床进展和商业性价值。

目录

第一章：序言

第二章：调查方法

• 调查设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查的前提
• 研究限制

第三章执行摘要

• 首席体验长观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会映射
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依药物类型分類的药物发现市场

• 生物製药
• 小分子药物

第九章 药物发现市场：依技术划分

• 生物分析仪器
• 生物晶片
• 生物资讯学
• 组合化学
• 高通量筛检
• 奈米科技
• 药物基因体学

第十章 药物研发市场：依治疗领域划分

• 心血管疾病
• 消化器官系统疾病
• 感染疾病及免疫系统疾病
• 神经病学
• 肿瘤学

第十一章 药物研发市场：依地区划分

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十二章 药物研发市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十三章 药物研发市场：依国家划分

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十四章：美国药物研发市场

第十五章：中国药物研发市场

第十六章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Abbott Laboratories
• Agilent Technologies, Inc.
• Alacrita Holdings Limited
• Amgen Inc.
• Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
• Astrazeneca PLC
• Atomwise, Inc.
• BenevolentAI
• Bio-Rad Laboratories, Inc.
• Merck & Co., Inc.

The Drug Discovery Market was valued at USD 81.11 billion in 2025 and is projected to grow to USD 92.53 billion in 2026, with a CAGR of 14.54%, reaching USD 209.87 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 81.11 billion
Estimated Year [2026]	USD 92.53 billion
Forecast Year [2032]	USD 209.87 billion
CAGR (%)	14.54%

Setting the stage for next-generation therapeutics and discovery platforms by summarizing technological drivers, regulatory pressures, and strategic priorities shaping innovation

The drug discovery landscape continues to evolve at an accelerated pace as biology, engineering, and data science converge to create new pathways from hypothesis to lead molecule. Advances in assay automation, computational chemistry, and multiomic analytics are compressing discovery timelines while regulatory frameworks and payer expectations are encouraging earlier demonstration of translational value. Against this backdrop, organizations must navigate a complex interplay of scientific opportunity and operational friction that ranges from reagent sourcing to late-stage translational validation.

In practical terms, this environment rewards disciplined portfolio management and cross-functional collaboration. Translational research groups, external innovation partners, and manufacturing teams must align around clear go/no-go criteria and de-risking milestones so that investment is concentrated on candidates with differentiated biology and plausible development pathways. Moreover, the growing importance of platform technologies and data interoperability means that digital readiness and analytic capability are as strategic as wet-lab prowess. As stakeholders evaluate where to deploy capital and talent, they should consider both near-term feasibility and longer-term platform value so that discovery efforts deliver sustainable competitive advantage.

Identifying the transformative scientific, technological, and business model shifts that are rewriting drug discovery workflows and accelerating translational research outcomes

Several transformative shifts are rewriting the operational and strategic contours of drug discovery. First, the integration of high-content data streams with machine learning is enabling hypothesis generation and candidate triage at scales that were previously impractical, shifting emphasis from serendipitous findings toward data-driven lead selection. Second, modularization of laboratory workflows through automation and standardized reagents reduces variability and enables reproducible experiments across distributed sites, which in turn supports global collaboration and faster iteration.

Third, advances in biologics engineering and small molecule convergence are expanding the addressable biological space, prompting cross-disciplinary teams to rethink target selection and modality strategy. Fourth, regulatory and payer expectations increasingly reward robust translational evidence earlier in development, which places a premium on predictive preclinical models and clinically relevant biomarkers. Finally, strategic partnerships-ranging from technology licensing to co-development alliances-are proliferating as organizations seek to combine complementary capabilities rather than build everything in-house. Together, these shifts demand that organizations adopt flexible operating models, invest in interoperable platforms, and cultivate partnerships that accelerate discovery while managing technical and commercial risk.

Analyzing the cumulative policy and tariff changes in the United States during 2025 and their ripple effects across supply chains, sourcing, and manufacturing strategies

Policy changes and tariff adjustments implemented in the United States during 2025 introduced new layers of complexity for sourcing reagents, instruments, and critical components used across discovery laboratories. Tariff adjustments affected imported laboratory equipment and certain biochemical reagents, prompting procurement teams to reassess supplier relationships, lead times, and total landed costs. In response, many organizations have shifted procurement strategies to emphasize dual sourcing, longer contract horizons, and closer collaboration with suppliers to secure priority allocations and mitigate disruption.

Operationally, elevated import costs led some groups to prioritize onshoring for high-value manufacturing steps or to negotiate volume-based agreements with regional suppliers. Concurrently, research organizations accelerated qualification of alternative reagents and reagents sharing across consortia to preserve experimental continuity. While these adjustments required near-term investment and process redesign, they also catalyzed longer-term supplier development and more robust risk management practices. Moving forward, discovery leaders should continue to monitor policy developments, embed tariff sensitivity into sourcing models, and maintain agile procurement protocols that can respond to sudden changes in cross-border trade conditions.

Uncovering segmentation-driven opportunity zones across drug types, enabling technologies, and therapeutic areas to inform prioritization and investment decisions

Segment-level perspective reveals differentiated implications for strategy, capability investment, and partnership design. When considering drug types, the distinct development pathways for Biologic Drugs versus Small Molecule Drugs shape upstream discovery priorities and downstream manufacturing decisions; biologics typically require deeper investment in expression systems and analytical characterization, while small molecules often emphasize medicinal chemistry, ADMET profiling, and scalable synthetic routes. In terms of enabling technologies, organizations can unlock value by targeting platform integration across Bioanalytical Instruments, Biochips, and Bioinformatics to enable high-resolution data capture and decision automation, while Combinatorial Chemistry and High Throughput Screening accelerate chemical diversity exploration and candidate identification. Nanotechnology and Pharmacogenomics further expand the toolkit for targeted delivery and patient stratification, enabling more precise translational strategies.

Therapeutic area segmentation also directs scientific focus and commercial planning. Oncology and Neurology demand complex translational models and specialized biomarker strategies, whereas Infectious & Immune system Diseases often require rapid-response capabilities and robust pathogen biology expertise. Cardiovascular Disease and Digestive System Diseases call for long-term safety profiling and population stratification considerations. These segmentation lenses together inform where firms should allocate discovery effort, which external partners to engage for specific capabilities, and how to stage investments in in-house platforms versus outsourced services to maximize scientific yield and operational resilience.

Examining regional dynamics and cross-border collaboration patterns that influence resource allocation, clinical trial placement, and manufacturing footprints worldwide

Regional dynamics materially influence where organizations locate capabilities, run trials, and source components. In the Americas, there is strong concentration of venture capital, specialist service providers, and translational infrastructure that supports rapid progression from lead discovery to clinic; this concentration encourages close proximity between discovery teams and clinical collaborators. Europe, Middle East & Africa combines deep scientific expertise, diverse regulatory environments, and an emphasis on collaborative research networks, making it attractive for consortium-based programs and adaptive trial designs. Asia-Pacific presents a mix of high-capacity manufacturing, rapidly growing biotech ecosystems, and a large patient population for clinical research, which makes it a strategic choice for scaling manufacturing and accelerating patient recruitment.

Because regulatory, reimbursement, and operational realities differ across these regions, organizations should design regional strategies that reflect local advantages while maintaining global coherence. This can be achieved by aligning clinical development plans to local regulatory pathways, establishing regional centers of excellence for core capabilities, and orchestrating cross-border data governance that enables reproducible science while meeting jurisdictional compliance requirements. Thoughtful regional allocation of assets and partnerships reduces time-to-insight and enhances the probability that translational findings will survive the transition from lab to clinic.

Profiling leading corporate actors and innovation collaborators to reveal competitive positioning, partnership trends, and capability gaps in discovery ecosystems

A focused view of corporate players and collaborative consortia highlights where capabilities concentrate and where gaps remain. Some organizations distinguish themselves through proprietary platforms that combine hardware, chemistry, and data analytics, enabling them to accelerate iterative discovery cycles and offer differentiated service models. Others pursue breadth through strategic alliances, building capability portfolios that include outsourced research providers, academic partnerships, and contract development organizations to access specialized expertise without bearing full fixed-cost burdens. In addition, a cohort of technology innovators is driving step-change improvements in assay sensitivity, miniaturization, and throughput, which forces incumbents to rethink operational models and investment priorities.

Across the ecosystem, successful actors demonstrate an ability to translate platform capability into translational evidence by integrating rigorous validation pathways and clinical relevance filters. They also manage intellectual property pragmatically, focusing on freedom-to-operate in key geographies while leveraging collaborative licensing to expand development capacity. For organizations assessing competitive positioning, the critical questions are whether to invest in unique platform development, pursue accretive partnerships to fill capability gaps, or adopt a hybrid approach that balances control and flexibility. The optimal path depends on portfolio ambitions, risk tolerance, and the pace at which a given therapeutic area requires clinical validation.

Delivering pragmatic, high-impact recommendations for industry leaders to align R&D pipelines, de-risk supply chains, and capitalize on emergent platform technologies

Industry leaders should take deliberate steps to align scientific ambition with operational capability while preserving optionality in an uncertain environment. First, strengthen platform interoperability by investing in data standards, modular automation, and validated analytics so that results generated in different labs or with different instruments remain comparable and actionable. Second, establish procurement and supplier development strategies that reduce single-source dependencies and incorporate contingency planning for cross-border disruptions. Third, prioritize translational validation early by integrating clinically oriented assays, patient-derived models, and biomarker development into discovery workflows to reduce downstream attrition.

In addition, leaders should cultivate a portfolio approach to externalization: selectively insource core differentiators while outsourcing standardized capabilities to high-quality partners. Complementing these operational moves, invest in talent programs that blend wet-lab expertise, data science, and regulatory insight, and align incentives to reward milestone-driven progress. Finally, pursue pragmatic collaboration models-such as time-limited consortia or milestone-based joint ventures-that enable rapid access to capability without long-term capital overhang. Taken together, these actions will help organizations convert scientific promise into sustainable pipelines and resilient operations.

Explaining the rigorous mixed-method research approach used to synthesize primary and secondary intelligence, ensuring reproducible insights and strategic relevance

The research underpinning these insights employed a mixed-methods approach that combined primary interviews, technical literature synthesis, and systematic capability mapping. Primary engagements included structured conversations with discovery scientists, procurement leaders, and regulatory experts to capture operational pain points and strategic priorities. Secondary sources encompassed peer-reviewed publications, regulatory guidance documents, and technology validation reports to verify technical claims and contextualize innovation trajectories. Data synthesis prioritized reproducibility and traceability, linking specific observations to source material and expert attribution.

To ensure rigor, capability assessments applied consistent evaluation frameworks across technologies and geographies, focusing on maturity, scalability, and translational relevance. Sensitivity analyses explored how variations in supply chain exposure, regulatory pathways, and partnership models could alter operational risk profiles. Throughout, findings were validated through cross-checks with domain experts and iterative review cycles, producing a set of insights designed to be actionable for executives and technical leaders alike.

Drawing conclusive perspectives that integrate technological, regulatory, and commercial factors to inform executive decision-making and strategic roadmaps

In conclusion, the current era of discovery demands that organizations be both scientifically ambitious and operationally disciplined. Breakthroughs in instrumentation, computational modeling, and translational biology create unprecedented opportunity, yet they operate within a reality of supply chain fragility, evolving policy landscapes, and heightened expectations for early clinical relevance. Those who integrate interoperable platforms, pragmatic partnership strategies, and robust supplier management will be better positioned to translate discovery into clinical progress and commercial value.

Moving from insight to impact requires targeted investments in platform integration, talent that spans disciplines, and procurement practices that reduce exposure to single points of failure. By marrying scientific rigor with strategic operational design, leaders can accelerate translational pathways, protect critical workflows from disruption, and sustain long-term innovation. These priorities should inform board-level discussions, R&D planning cycles, and cross-functional initiatives to ensure that discovery efforts remain resilient, focused, and aligned with patient and payer expectations.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Market, by Drug Type

• 8.1. Biologic Drugs
• 8.2. Small Molecule Drugs

9. Drug Discovery Market, by Technology

• 9.1. Bioanalytical Instruments
• 9.2. Biochips
• 9.3. Bioinformatics
• 9.4. Combinatorial Chemistry
• 9.5. High Throughput Screening
• 9.6. Nanotechnology
• 9.7. Pharmacogenomics

10. Drug Discovery Market, by Therapeutic Area

• 10.1. Cardiovascular Disease
• 10.2. Digestive System Diseases
• 10.3. Infectious & Immune system Diseases
• 10.4. Neurology
• 10.5. Oncology

11. Drug Discovery Market, by Region

• 11.1. Americas
  • 11.1.1. North America
  • 11.1.2. Latin America
• 11.2. Europe, Middle East & Africa
  • 11.2.1. Europe
  • 11.2.2. Middle East
  • 11.2.3. Africa
• 11.3. Asia-Pacific

12. Drug Discovery Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Drug Discovery Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. United States Drug Discovery Market

15. China Drug Discovery Market

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025
• 16.5. Abbott Laboratories
• 16.6. Agilent Technologies, Inc.
• 16.7. Alacrita Holdings Limited
• 16.8. Amgen Inc.
• 16.9. Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
• 16.10. Astrazeneca PLC
• 16.11. Atomwise, Inc.
• 16.12. BenevolentAI
• 16.13. Bio-Rad Laboratories, Inc.
• 16.14. Merck & Co., Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. UNITED STATES DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 11. CHINA DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. AMERICAS DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 49. AMERICAS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 50. AMERICAS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 51. AMERICAS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 52. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 54. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 55. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 56. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 58. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 59. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 61. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 62. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 63. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 64. EUROPE DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 65. EUROPE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 66. EUROPE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 67. EUROPE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 68. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 69. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 70. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 71. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 72. AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 73. AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 74. AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 75. AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 76. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 77. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 78. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 79. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 81. ASEAN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 82. ASEAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 83. ASEAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 84. ASEAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 85. GCC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 86. GCC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 87. GCC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 88. GCC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 89. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 90. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 91. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 92. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 93. BRICS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 94. BRICS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 95. BRICS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 96. BRICS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 97. G7 DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 98. G7 DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 99. G7 DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 100. G7 DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 101. NATO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 102. NATO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 103. NATO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 104. NATO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 105. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. UNITED STATES DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 107. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 108. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 109. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 110. CHINA DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 111. CHINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 112. CHINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 113. CHINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)